Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4700 · 1 trial · 1 indication
The occurrence of any of the following toxicities during Cycle 1 will be considered a DLT, if assessed by the investigator related to study intervention administration: * Grade 4 nonhematologic toxicity * Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia * Any nonhematologic AE ≥Grade 3 in severity, with exceptions * Any Grade 3 or Grade 4 nonhematologic laboratory value, as with pre-specified exceptions * Any Grade 3 or Grade 4 laboratory abnormalities, with the exceptions * Febrile neutropenia Grade 3 or Grade 4 * Prolonged delay (\>2 weeks) in initiating Cycle 2 due to intervention-related toxicity * Any study drug toxicity that causes the participant to discontinue study drug during Cycle 1 * Missing \>25% of MK-4700 doses as a result of drug-related AEs during the first cycle * Grade 5 toxicity
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Arm | Type | Description |
|---|---|---|
| Arm 1: MK-4700 | EXPERIMENTAL | Participants receive escalating doses every three weeks (Q3W) of MK-4700 for a maximum of 35 cycles (approximately 2 years; cycles are 21 days in length). Eligible participants enrolled in Arm 1 who experience progressive disease (PD) may cross over to Arm 2 to receive MK-4700 and pembrolizumab combination therapy. |
| Arm 2: MK-4700 + Pembrolizumab | EXPERIMENTAL | Participants will receive MK-4700 and pembrolizumab Q3W for up to 35 cycles (approximately 2 years) or until PD, death, toxicity, or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| MK-4700 | BIOLOGICAL | Administered via subcutaneous (SC) injection |
| Pembrolizumab | BIOLOGICAL | Administered via intravenous infusion |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report who have experienced disease progression on or after prior anti-cancer treatments, or been intolerant to,...
MK-4700 is an investigational monoclonal antibody being studied for the treatment of malignant neoplasms, which are cancerous tumors. It is being developed by Merck & Company, Inc. for use in oncology, specifically in patients with advanced or metastatic solid tumors.
The specific molecular target of MK-4700 is not disclosed in the available information. It is described as a monoclonal antibody, which typically works by binding to a specific protein involved in cancer growth, but the exact target has not been publicly specified.
MK-4700 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research on this investigational drug for oncology indications.
MK-4700 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with advanced or metastatic solid tumors.
MK-4700 has been studied in one clinical trial with the identifier NCT06894771, titled "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)." This Phase 1 trial has been completed and enrolled 5 participants.
No, MK-4700 is not the same as pembrolizumab. Pembrolizumab is a separate drug, also developed by Merck, that is being studied in combination with MK-4700 in clinical trial NCT06894771. MK-4700 is a distinct investigational monoclonal antibody being evaluated alone or with pembrolizumab.